Last reviewed · How we verify
NCT07407465: CHIMERA
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
Phase 2 trial testing Trastuzumab-Deruxtecan (T-DXd) in Colorectal Cancer in 42 participants. Currently enrolling.
20 October 2027
Quick facts
| Lead sponsor | Gruppo Oncologico del Nord-Ovest |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 42 |
| Start date | 20 October 2025 |
| Primary completion | 20 October 2027 |
| Estimated completion | 20 October 2027 |
| Sites | 28 locations across France, Spain, Germany, Italy |
Drugs / interventions tested
- Trastuzumab-Deruxtecan (T-DXd)
- Capecitabine (capecitabine) — full drug profile →
- Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Colorectal Adenocarcinoma — all drugs for Colorectal Adenocarcinoma →
- Rectal Adenocarcinoma — all drugs for Rectal Adenocarcinoma →
- Rectal Cancer, Adenocarcinoma — all drugs for Rectal Cancer, Adenocarcinoma →
Sponsor
Gruppo Oncologico del Nord-Ovest — full company profile →
Who can join
18 and older, any sex, with Colorectal Cancer or Colorectal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to evaluate the activity of first-line trastuzumab-deruxtecan, capecitabine and bevacizumab in terms of overall response rate for patients with HER-2 positive metastatic/locally advanced unresectable colorectal cancer
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07407465
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Gruppo Oncologico del Nord-Ovest trials
Trials by the same sponsor.
- NCT06897644 — Gemcitabine Plus Nab-paclitaxel as Switch Maintenance Versus Continuation of Modified FOLFIRINOX as 1st Line Chemotherap · Phase 3 · recruiting
- NCT06869473 — Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for R · Phase 2 · recruiting
- NCT06733038 — FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorect · Phase 3 · recruiting
- NCT06578559 — Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC · Phase 2 · active not recruiting
- NCT06332079 — Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07407465 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gruppo Oncologico del Nord-Ovest
- Last refreshed: 17 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07407465.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing